Insight Molecular Diagnostics (IMDX) Receivables (2020 - 2025)
Historic Receivables for Insight Molecular Diagnostics (IMDX) over the last 6 years, with Q3 2025 value amounting to $258000.0.
- Insight Molecular Diagnostics' Receivables rose 2344.5% to $258000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $258000.0, marking a year-over-year increase of 2344.5%. This contributed to the annual value of $1.6 million for FY2024, which is 23326.45% up from last year.
- As of Q3 2025, Insight Molecular Diagnostics' Receivables stood at $258000.0, which was up 2344.5% from $512000.0 recorded in Q2 2025.
- In the past 5 years, Insight Molecular Diagnostics' Receivables ranged from a high of $3.5 million in Q1 2025 and a low of $85000.0 during Q2 2024
- In the last 5 years, Insight Molecular Diagnostics' Receivables had a median value of $1.0 million in 2021 and averaged $1.1 million.
- In the last 5 years, Insight Molecular Diagnostics' Receivables skyrocketed by 530769.23% in 2021 and then crashed by 8850.0% in 2024.
- Insight Molecular Diagnostics' Receivables (Quarter) stood at $1.4 million in 2021, then dropped by 2.57% to $1.4 million in 2022, then tumbled by 65.43% to $484000.0 in 2023, then soared by 233.26% to $1.6 million in 2024, then plummeted by 84.0% to $258000.0 in 2025.
- Its Receivables stands at $258000.0 for Q3 2025, versus $512000.0 for Q2 2025 and $3.5 million for Q1 2025.